SCHEMBL221801

SCHEMBL221801

COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)C2(C(=O)Nc3cc(Cl)ccc32)[C@H]1c1cccc(Cl)c1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 20/20 1.00
TP53 P04637 5/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221800 1.00 MDM2 (1.00) MDM2TP53
SCHEMBL29776615 1.00 MDM2 (1.00) MDM2TP53
SCHEMBL10299795 1.00 MDM2 (1.00) MDM2TP53
SCHEMBL222901 1.00 MDM2 (1.00) MDM2TP53
SCHEMBL222900 1.00 MDM2 (1.00) MDM2TP53
SCHEMBL29776561 0.95 MDM2 (0.90) MDM2TP53
SCHEMBL222465 0.95 MDM2 (0.90) MDM2TP53
SCHEMBL1956570 0.95 MDM2 (0.90) MDM2TP53
SCHEMBL222469 0.95 MDM2 (0.90) MDM2TP53
SCHEMBL10299791 0.95 MDM2 (0.90) MDM2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3498712-B1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF JIANGSU YAYO BIOTECHNOLOGY CO LTD (CN) 2024-01-03 EP claimed
US-8088815-B2 Spiroindolinone pyrrolidines HOFFMAN-LA ROCHE INC. (US) 2012-01-03 US claimed
EP-3498712-B1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF JIANGSU YAYO BIOTECHNOLOGY CO LTD (CN) 2024-01-03 EP disclosed
US-10471154-B2 Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof Xiao, Fei (CN) 2019-11-12 US disclosed
US-10471154-B2 Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof Xiao, Fei (CN) 2019-11-12 US disclosed
US-20190209700-A1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF JIANGSU YAYO BIOTECHNOLOGY CO. LTD. (CN) 2019-07-11 US disclosed
US-20190209700-A1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF JIANGSU YAYO BIOTECHNOLOGY CO. LTD. (CN) 2019-07-11 US disclosed
EP-3498712-A1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF Xiao, Fei (CN) 2019-06-19 EP disclosed
EP-3498712-A1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF Xiao, Fei (CN) 2019-06-19 EP disclosed
WO-2018027477-A1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF 肖飞 2018-02-15 WO disclosed
US-8088815-B2 Spiroindolinone pyrrolidines HOFFMAN-LA ROCHE INC. (US) 2012-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10471154-B2 Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof SI, MKI67, HSD17B7 MDM2 633/4885TP53 43/4885
US-20190209700-A1 SPIROCYCLIC INDOLONE POLYETHYLENE GLYCOL CARBONATE COMPOUND, COMPOSITION, PREPARATION METHOD AND USE THEREOF SI, HSD17B7, MKI67 MDM2 621/4885TP53 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.